Physician profile
Audrey Huffman
NPI 1790329027
$927.90
in general payments reported to CMS, 2019-2025
22 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.90 · 2022: $193 · 2023: $151 · 2024: $291 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $168.96 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $123.42 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $72.87 | 2022-2025 | Inceptiv |
| Abbvie INC. | $68.75 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.81 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $45.96 | 2023-2024 | Cologuard Collection Kit |
| Inari Medical, INC. | $43.41 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Phathom Pharmaceuticals, INC. | $42.66 | 2024-2025 | Voquezna |
| Insulet Corporation | $32.42 | 2023-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $32.24 | 2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $31.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $30.02 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $23.56 | 2025 | |
| Kyowa Kirin, INC. | $20.32 | 2025 | |
| Philips North America LLC | $19.80 | 2024 | (Ck4) Mcot |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.77 | 2025 | |
| Biodelivery Sciences International, INC. | $16.43 | 2021 | |
| Amarin Pharma, INC. | $15.58 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.57 | 2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $13.30 | 2024 | |
| Inspire Medical Systems, INC. | $12.91 | 2023 | Inspire |
| Genentech USA, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.